3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Breast Neoplasms
11
Stomach Neoplasms
10
Urinary Bladder Neoplasms
6
Carcinoma, Transitional Cell
5
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Ovarian Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
2
HER2-positive Gastric Cancer
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Cancer Recurrent
1
Neoplasms
1
Muscle Invasive Bladder Carcinoma
1
Muscle Invasive Bladder Cancer (MIBC)
1
Muscle Invasive Bladder Cancer
1
Metastatic HER2 Positive Gastroesophageal Junction Cancer
1
Lung Neoplasms
1
High-risk Non-muscle Invasive Bladder Cancer
1
Head and Neck Neoplasms
1
HER2-positive Metastatic Breast Cancer
1
HER2-low Breast Cancer
1
Gastric Adenocarcinoma
1
Endometrial Neoplasms
1
Castration-resistant Prostate Cancer
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
180
Gemcitabine
168
Paclitaxel
150
Carboplatin
134
Bevacizumab
126
Cisplatin
113
Docetaxel
112
Cyclophosphamide
109
Exercise
97
Nivolumab
93
Fluorouracil
88
Capecitabine
85
Dexamethasone
81
Irinotecan
74
Radiotherapy
68
Oxaliplatin
68
Pemetrexed
66
Standard of Care
64
Leucovorin
63
Cetuximab
59
Sorafenib
53
Erlotinib Hydrochloride
53
Drug Therapy
53
Blood Specimen Collection
51
Doxorubicin
50
atezolizumab
48
trametinib
47
Ipilimumab
47
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
42
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms
×
disitamab vedotin
×
Clear all
NCT07142200
2025-08-26
DECIDING
RenJi Hospital
Phase 2
Not yet recruiting
45 enrolled